logo
There's no escaping wildfire smoke indoors, experts say — but it can help

There's no escaping wildfire smoke indoors, experts say — but it can help

It's been a
smoky summer for Toronto
, with forest fires in the Prairies once again pushing the city's Air Quality Health Index into the 'high risk' category Thursday morning.
Environment Canada has issued a special statement
urging Torontonians to limit their time outdoors where possible. But there's no escaping the smoke even when inside, experts tell the Star.
Most buildings are only able to keep about half — 40 to 60 per cent — of outdoor air pollutants from coming inside, according to the research of Jeffrey Brook, an associate professor at the University of Toronto's Dalla Lana School of Public Health.
As climate change advances, I cannot grasp the hugeness of the calamity. What once was notable is becoming a habit, a toxic, sinister pattern.
As climate change advances, I cannot grasp the hugeness of the calamity. What once was notable is becoming a habit, a toxic, sinister pattern.
That means, on especially smoky days, indoor air quality can still reach dangerous levels for susceptible individuals, Brook and other experts previously told the Star. These can include young children, pregnant people, elderly individuals and those with respiratory or cardiovascular conditions like asthma.
'There's a lot of epidemiology research that says (pollutants released by wildfires) is a major killer,' Brook explained. 'It's one of the most
significant causes of premature mortality
in the world.'
And yet, our building codes and ventilation systems generally aren't designed to prioritize smoke and other pollutants, experts say. As the
climate crisis
makes wildfires a more common occurrence, policymakers are being urged to consider long-term solutions to a worsening issue.
There are three main ways smoke (and other air pollutants) can infiltrate our homes, according to Amy Li, an assistant professor of civil and environmental engineering at the University of Waterloo.
The first is through any large openings, like a door left ajar or an opened window. 'This is why we often have the recommendation to close all windows and doors when we know the outdoor air is not good,' she explained.
The second pathway is less visible — leaks and cracks in a home's enclosure through which pollutants can enter. 'Buildings are not like a spaceship,' Li said. 'There will always be some amount (of pollutants) getting into the building.'
Health experts are not currently concerned about air quality in Toronto but warn prolonged exposure to moderate risk air may threaten health.
Health experts are not currently concerned about air quality in Toronto but warn prolonged exposure to moderate risk air may threaten health.
The third is through mechanical ventilation systems that funnel outside air indoors, said Jeffrey Siegel, a professor of civil engineering at the University of Toronto. This sort of system is present in 'most non-residential buildings,' he said.
It's why large commercial and institutional buildings, like schools, offices and community centres, are often more vulnerable to smoke, Li added, although it varies from building to building.
Older buildings also tend to have more cracks for pollutants to seep through and ventilation systems less able to keep smoke out, Li and Siegel explained. Meanwhile, single family homes and townhouses tend to be 'leakier' compared to highrise apartment complexes, Li said.
Buildings without air conditioning are also at greater risk if windows are kept open to regulate high temperatures, Siegel added.
The first rule of thumb is to close any doors and windows when it's smoky out. You might even consider taping windows shut if leaks are present, Li said. 'That's not as protective as would be ideal because of the leaks in buildings … but it will help,' Siegel added.
But this may not be an option if your residence has no air conditioning and you're weathering a period of extreme heat: 'The health effects of extreme heat can be more serious than the effects of wildfire smoke,' Siegel said.
If your home has a central forced air system with a MERV 11-rated air filter or better, Siegel recommends keeping your fan going continuously if possible. MERV, or 'minimum efficiency reporting values,' measures how efficiently a filter can capture particles; a MERV 13 to 15 rated filter is preferred, Siegel said.
Unlike many commercial buildings, most residences in Canada recirculate the indoor air instead of pumping in fresh air from the outside, Li said.
TORONTO - The Canadian Ophthalmological Society is urging people to take care of their eyes as wildfires burn across Manitoba and Saskatchewan.
TORONTO - The Canadian Ophthalmological Society is urging people to take care of their eyes as wildfires burn across Manitoba and Saskatchewan.
Siegel also recommended running portable air filters in crowded spaces, especially in areas with susceptible individuals.
The Star previously outlined how to make an affordable filter
using a fan, air filters, duct tape and cardboard.
If possible, Li recommends upgrading your home's filtration system. Consult with a professional first, especially if your home's ventilation system is old, as a high-efficiency filter might overwhelm the system and lead to drops in pressure, she said.
Finally, those at high risk can consider wearing a well-fitted respirator or mask, like an N95 mask, while indoors when it's especially smoky, Siegel explained.
Until recently, building filtration systems have placed less emphasis on keeping wildfire smoke and other environmental pollutants out, Brook noted. And while the COVID-19 pandemic saw a shift toward improving HVAC systems in buildings like schools,
experts and advocates have noted it's not sufficient
to keep up with the increasing prevalence of wildfires.
Almost any upgrades to a building will also make it more resistant to wildfire smoke, Siegel said, from installing new windows to heating, ventilation and air-conditioning retrofits.
The problem is many of the buildings where these improvements are needed most, like schools, are unable to implement them due to budget and funding limitations, he continued.
For urbanites, there's a new way to mark the calendar: the day the smoke reaches the city.
For urbanites, there's a new way to mark the calendar: the day the smoke reaches the city.
'It's an important area that we should be thinking about for investment, because the issue isn't just wildfire smoke,' Siegel said. 'We have increasing ambient air pollution just because of urbanization. We have a lot more construction, a lot more traffic, a lot of major roadways with schools and other buildings near them.'
There's another hurdle. Brook noted that improved ventilation, air-conditioning and filtration systems may end up contributing to the climate crisis.
'If you just start expending more energy to make the indoor air clean, it can becomes a vicious cycle of more emissions if our energy is coming from dirty sources,' he said.
'We have to think, what's our long-term strategy?' Brook continued. 'Why have we stopped talking about how we're going to meet carbon emission targets? How are we going to upgrade our housing and clean air while not increasing our energy usages?'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

5 Billion Sea Stars Have Shattered and Died Over the Past 10 Years, Scientists May Finally Know Why
5 Billion Sea Stars Have Shattered and Died Over the Past 10 Years, Scientists May Finally Know Why

Yahoo

time15 hours ago

  • Yahoo

5 Billion Sea Stars Have Shattered and Died Over the Past 10 Years, Scientists May Finally Know Why

A team of international researchers discovered the cause of a sea-star wasting diseaseNEED TO KNOW The cause of a sea star-wasting disease was determined to be a bacterium known as Vibrio pectenicida The disease causes sea stars to disintegrate to death in a white, goo-like substance An estimated 95% of sunflower sea stars died during the 10-year epidemicAfter an estimated 5 billion sea stars died due to a wasting disease in oceans globally, scientists have identified the root cause of the disease. A team of researchers identified the cause as a bacterium known as Vibrio pectenicida. The team reported its findings this week in Nature Ecology & Evolution. The disease causes starfish to disintegrate into a white, slimy substance. The disease is the largest documented epidemic for a noncommercial species, and it has affected more than 20 species of sea stars along the West Coast of North America, Scientific American reports. An estimated 90% of sunflower sea stars ( known as Pycnopodia helianthoides) have died from the illness, making them a critically endangered species. Sunflower sea stars are capable of sprouting 24 arms and growing to the size of a bicycle tire, per the Associated Press. The epidemic has lasted a decade. The same strain of bacteria has also infected shellfish. The international research project was led by scientists from the Hakai Institute, the University of British Columbia (UBC), and the University of Washington—and conducted in collaboration with The Nature Conservancy, the Tula Foundation, the U.S. Geological Survey's Western Fisheries Research Center, and the Washington Department of Fish and Wildlife. The first author on the study and an evolutionary ecologist at the Hakai Institute and UBC, Melanie Prentice, told Tula: "When we lose billions of sea stars, that really shifts the ecological dynamics.' Prentice went on to describe the impact of losing a sea star. 'In the absence of sunflower stars, sea urchin populations increase, which means the loss of kelp forests, and that has broad implications for all the other marine species and humans that rely on them," she explained. "So losing a sea star goes far beyond the loss of that single species.' Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer​​, from celebrity news to compelling human interest stories. With the sharp decline in sea stars, the sea urchins that usually serve as a food source rapidly expanded in population. In turn, they ate nearly 95% of the kelp forests in Northern California within a decade. These kelp forests help provide food and habitats for a wide variety of marine life, including fish, sea otters and seals, per the AP. With these new findings, researchers are hoping to revive the sea star population and restore balance to the ecosystem, the outlet reported. Read the original article on People

Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial
Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial

Business Wire

timea day ago

  • Business Wire

Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial

DALLAS--(BUSINESS WIRE)-- Starlight Therapeutics, a wholly owned subsidiary of Lantern Pharma Inc. (NASDAQ: LTRN), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for a Phase Ib/2a clinical trial to evaluate STAR-001 (LP-184) in combination with spironolactone for patients with glioblastoma multiforme (GBM) at first progression. "GBM remains one of the most difficult cancers to treat, with virtually no meaningful therapeutic advances in nearly 17 years. We believe our unique combination approach has the potential to offer new hope for patients and their families." Dr. Chamberlain Share The planned Phase Ib/2a clinical trial (IND 178511) is designed to investigate the safety, tolerability, and preliminary efficacy of STAR-001 in combination with spironolactone in patients with recurrent GBM, one of the deadliest and most aggressive forms of brain cancer. GBM represents approximately 15% of all brain tumors and has a median survival of approximately 12 months from initial diagnosis, with fewer than 5% of patients surviving beyond five years. "This FDA clearance represents a significant milestone for Starlight Therapeutics and our mission to bring innovative treatment options to patients facing the most challenging forms of brain and CNS cancers," said Dr. Marc Chamberlain, Chief Medical Officer of Starlight Therapeutics. "GBM remains one of the most difficult cancers to treat, with virtually no meaningful therapeutic advances in nearly 17 years. We believe our unique combination approach has the potential to offer new hope for patients and their families while advancing a novel mechanism to challenge these recurrent brain cancers." Targeting GBM Through Innovative Synthetic Lethality STAR-001 (also referred to as LP-184 when focused on other solid tumor indications) is a synthetically lethal, brain-penetrant, novel DNA-damaging agent that has demonstrated promising preclinical activity against various solid tumors, including pediatric and adult brain cancers. Lantern Pharma has previously been awarded both FDA Orphan Drug Designation and FDA Fast Track Designation for STAR-001 in GBM, underscoring the significant unmet medical need and the drug's potential to address it. An existing Phase 1a trial to determine safety, dosing, the maximum tolerated dose (MTD) and tolerability across a range of solid tumors, including GBM, is currently underway and expected to complete enrollment in the current quarter. This trial is expected to help establish a baseline dosing level and expectations of drug-concentration in tumor and plasma for future clinical trials, including those being planned by Starlight Therapeutics. The combination of STAR-001 with spironolactone, an existing FDA approved drug, represents a scientifically rational approach to treating GBM. STAR-001 is a blood-brain barrier permeable small molecule that leverages synthetic lethality to exploit DNA damage repair (DDR) deficiencies, particularly those overexpressing PTGR1. Approximately 60% of GBM cells overexpress PTGR1 levels sufficient to activate STAR-001. Spironolactone significantly enhances this therapeutic effect by inducing degradation of ERCC3, a critical protein involved in nucleotide excision repair (NER). This mechanism leads to NER deficiency (NERD), making GBM cells significantly more sensitive to STAR-001 and less capable of repairing the DNA damage caused by the administration of STAR-001. This synergistic approach is particularly promising in GBM which has often become resistant to therapies in the recurrent setting. AI-Driven Drug Development Platform Starlight Therapeutics was formed to pursue the focused clinical development of central nervous system (CNS) oncology indications developed and advanced through Lantern Pharma's proprietary artificial intelligence drug development platform, RADR®. This AI-driven approach enables the identification of optimal drug-cancer combinations and patient populations most likely to benefit from treatment, significantly reducing the time and cost typically associated with traditional drug development. "The clearance of this IND demonstrates the power of our efficient, data-driven drug development model in identifying promising therapeutic opportunities in areas of high unmet medical need," said Panna Sharma, President and CEO of Lantern Pharma. "Through Starlight Therapeutics, we are positioned to dedicate focused resources and expertise to advancing treatments for some of the most challenging cancers affecting the brain and central nervous system in both adults and children, while developing meaningful therapies that can reach patients in an accelerated timeline compared to traditional drug development processes." Market Opportunity and Next Steps With GBM representing an annual market opportunity of $3 to $5 billion globally and case numbers accelerating worldwide, there is an urgent need for innovative treatment approaches. The current standard of care has remained largely unchanged for over 15 years, highlighting the critical importance of novel therapeutic strategies like the STAR-001 combination. Starlight is targeting commencement of the Phase Ib/2a trial in late 2025 or early 2026, subject to additional funding, and plans to provide regular updates on trial preparation, patient enrollment progress, and preliminary data as they become available. About Glioblastoma Multiforme (GBM) Glioblastoma multiforme is the most common and aggressive form of primary brain tumor in adults, accounting for approximately 15% of all brain tumors. Despite aggressive multimodal treatment including surgery, radiation, and chemotherapy, the prognosis remains extremely poor, with a median survival of only 12 months and a five-year survival rate of less than 5%. The blood-brain barrier presents a significant challenge in treating GBM, as most therapeutic agents cannot effectively penetrate brain tissue. About Starlight Therapeutics Starlight Therapeutics is a wholly owned subsidiary of Lantern Pharma Corp., specifically focused on the clinical development of innovative treatments for central nervous system oncology indications. The company leverages Lantern Pharma's proprietary AI drug development platform to identify and advance promising therapeutic combinations for adult and pediatric patients with brain and CNS cancers. About Lantern Pharma Lantern Pharma (NASDAQ: LTRN) is an AI company transforming the cost, time, and failure rate of oncology drug discovery and development. Lantern's proprietary AI platform RADR® uses machine learning and multiomic data to solve complex, billion-dollar drug development challenges. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, Lantern has built a pipeline of promising, clinical stage drug candidates, including molecules that target novel cancer mechanisms and targets. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; estimates and plans regarding our subsidiary Starlight Therapeutics Inc. and the product candidate STAR-001; our strategic plans to advance the development of our drug candidates, including STAR-001, and our antibody drug conjugate (ADC) development program; estimates regarding the development timing for STAR-001; expectations and estimates regarding clinical trial timing and patient enrollment; our research and development efforts of our internal drug discovery programs and the utilization of our RADR® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding patient populations, potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "model," "objective," "aim," "upcoming," "should," "will," "would," or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the risk that we may not be able to secure sufficient future funding when needed and as required to advance and support our existing and planned clinical trials and operations, (ii) the risk that observations in preclinical studies and early or preliminary observations in clinical studies do not ensure that later observations, studies and development will be consistent or successful, (iii) the risk that our research and the research of our collaborators may not be successful, (iv) the risk that we may not be successful in licensing potential candidates or in completing potential partnerships and collaborations, (v) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (vi) the risk that no drug product based on our proprietary RADR® AI platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (vii) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission on March 27, 2025. You may access our Annual Report on Form 10-K for the year ended December 31, 2024 under the investor SEC filings tab of our website at or on the SEC's website at Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.

"That Ozempic kicks in quick" - Arenas accuses Doncic of using weight-loss drug to get in shape
"That Ozempic kicks in quick" - Arenas accuses Doncic of using weight-loss drug to get in shape

Yahoo

time2 days ago

  • Yahoo

"That Ozempic kicks in quick" - Arenas accuses Doncic of using weight-loss drug to get in shape

"That Ozempic kicks in quick" - Arenas accuses Doncic of using weight-loss drug to get in shape originally appeared on Basketball Network. Luka Doncic's stunning body transformation has left everyone in awe. In just two months, the Slovenian shed the "Fat Luka" image and landed on the cover of "Men's Health" magazine. While most people are praising him for his determination to get in shape, former Washington Wizards All-Star guard Gilbert Arenas believes that Doncic turned into "Slim Luka" with the help of a weight-loss drug. "Let's just be honest, man. The fact he showed you with enough time of rest that Ozempic kicks in quick. Listen, I heard all the soups and s–t and you know he eat this, he eat that. Cool, right? All it takes is a boop shot every week, and you like that. So he's willing to do whatever it takes to get down," said Arenas. Not the first time that Ozempic was mentioned with Luka Ozempic is a prescription drug primarily used as an anti-diabetic medication. According to a once-a-week injection of the medicine, coupled with the proper diet and exercise, can improve blood sugar levels in people with Type 2 diabetes. However, because it can suppress hunger and promote the feeling of fullness, doctors use it off-label for weight loss. Curiously, Arenas isn't the first to link Doncic's incredible transformation to Ozempic. During his recent appearance on "Good Morning America", host Craig Melvin recklessly asked Luka if he took Ozempic shots, and he just nodded his head before saying "no." In the "Men's Health" featured article, Luka attributed his weight loss to a strict diet, exercise, and hard work. He said he did not touch a basketball for a month to focus on his body, and since June, Doncic has been on an intermittent fasting plan aimed at limiting inflammation and helping his body recover won't make Luka a better defender However, while Gil questions how Luka got there, he does not doubt that with his Ozempic-aided body, he will dominate the league like never before. Arenas said if Doncic could lead the Dallas Mavericks to the NBA Finals and average 30 points per game, there's no question he'll easily post a 39-9-9 stat line next season. However, Agent Zero says he doesn't believe the Slovenian's new physique will make him a better defender. "Now, the fact that he was doing what he was doing, while he was fat. What do you think he's gonna do to these ni—s now? He's about to go ham. I don't want to hear nothing about no defense, okay? He's not losing weight to play no defense. He lost weight to see if they can play some defense," he added. Fat or not, Luka's ability to playmake and score points was never questioned. It was his defense that everyone frowned at. In his press conference, Doncic joked that new teammate Marcus Smart will help with some tips on that end of the court, but Gil said that "Slim Luka" won't become a better defender. However, it will make him a more dangerous offensive story was originally reported by Basketball Network on Aug 5, 2025, where it first appeared.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store